Clinical Trial: A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857279) titled 'A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma' on Feb. 27.

Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Study Start Date: April 21

Study Type: INTERVENTIONAL

Condition: Carcinoma of Head And/or Neck

Intervention: DRUG: HLX43 DOSE 1

Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibito...